공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

산화기(Oxygenator) 시장 : 성장, 동향, 예측(2020-2025년)

Oxygenators Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 928059
페이지 정보 영문
가격
US $ 4,250 ₩ 4,793,000 PDF (Single User License)
US $ 4,750 ₩ 5,357,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,766,000 PDF (Site License)
US $ 7,500 ₩ 8,458,000 PDF (Corporate License)


산화기(Oxygenator) 시장 : 성장, 동향, 예측(2020-2025년) Oxygenators Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 산화기 시장은 예측기간 동안 약 7.8%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측됩니다.

세계의 산화기(Oxygenators) 시장에 대해 조사했으며, 시장 기회 및 동향, 성장 촉진요인 및 억제요인, 제품 유형·용도·지역별 시장 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 뇌졸중이나 죽음에 이르는 비대 심근증 등 심장장애 유병률 상승
    • 노인인구 증가와 가처분소득 증가에 따른 세계 의료 지출 증가
    • 기술적으로 진보한 제품의 이용 가능성 및 상환 정책
  • 시장 성장 억제요인
    • 경피적 관상동맥 중재술과 같은 최소침습술 채용과 산소 시스템과 관련된 리스크
    • 성능 기준을 준수해야 하는 Class II 카테고리 기기의 엄격한 FDA 규제
  • Porter's Five Force 분석

제5장 시장 세분화

  • 제품 유형별
    • 기포형 산화기
    • 막형 산화기
  • 용도별
    • 호흡기
    • 심장
    • 체외 심폐소생술(ECPR)
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • Chalice Medical Ltd
    • EUROSETS Srl
    • Getinge AB
    • Livanova Plc
    • Medtronic plc
    • Microport Scientific Corporation
    • Nipro Medical Corporation
    • Terumo Medical Corporation
    • Braile Biomedica
    • Xenios AG

제7장 시장 기회 및 향후 동향

LSH 20.06.02

The oxygenators market was valued at USD 207 million in 2020, and it is poised to grow at a CAGR of 5.4% during the forecast period, 2021-2026, to reach USD 297 million by 2026.

To cope up with the current COVID-19 situation, companies are increasing the production of oxygenators globally to support the adoption of ECMO procedures for the treatment of COVID-19 patients. There has been a huge increase in demand for oxygenators in ICU units. In addition, these devices have the most significant aspects of critical care in surgical procedures and the management of COVID-19 patients; therefore, market players are launching products associated with an oxygenator. COVID-19 also impacted the production of oxygenator products in 2020. Furthermore, the delay of elective procedures due to COVID-19-related measures adversely affected medical devices such as oxygenators, especially in the first half of 2020.

The major factors driving the growth of the market are the global prevalence of various coronary heart diseases and strokes due to changing lifestyles, leading to a rise in surgical interventions, favorable reimbursement initiatives, and rapid growth of the geriatric population. For instance, according to the Global Health and Wellness Report published in 2018, nearly 40% of the adult population in the United States were diagnosed with a cardiovascular condition, which directly resulted in higher demand for coronary artery bypass procedures, leading to a rising focus on oxygenators for efficient treatments, fueling the growth of the market throughout the forecast period.

Moreover, there is a rising burden of cardiovascular diseases across the world, and they are the leading causes of death. As per the 2020 statistics provided by the World Health Organization (WHO), ischemic heart disease is responsible for 16% of the world's total deaths. As per the same source, an estimate of 8.9 million deaths were reported for ischemic heart disease in 2019. The rising prevalence of cardiovascular diseases is driving cardiopulmonary surgeries and coronary artery bypass grafting (CABG), which may increase the demand for oxygenators.

However, the adoption of minimally invasive procedures, like percutaneous coronary interventions, risks associated with oxygenation systems, and stringent United States FDA regulations for Class II category devices, which should comply with the performance standards, are acting as barriers for the overall market growth.

Key Market Trends

The Membrane Oxygenators Segment is Expected to Hold the Largest Market Share

The membrane oxygenators segment is expected to witness the largest market share during the forecast period due to their rising adoption in CABG procedures and extracorporeal circulation for cardiopulmonary support in various surgical procedures along with heart-lung machines due to advantages such as reduction of the damage of tissues and thrombosis compared to bubble oxygenators. Also, their rapid deployability, effective gas exchange in a relatively small membrane surface area, enhanced blood flows, less hemolysis, and less post-operative bleeding further boost the growth of the segment.

Based on application, the respiratory segment is expected to hold a major market share during the forecast period. This can be attributed to the rise in the prevalence of chronic obstructive pulmonary disease (COPD) and cardiopulmonary diseases.

Moreover, in April 2020, an Indian firm, Genrich Membranes, which the being funded by the Department of Science and Technology (DST), India, developed membrane oxygenator equipment for the treatment of COVID-19 patients. Hence, companies are working on manufacturing oxygenators as the surgeries that were put on hold during the initial days are now resuming, and thus, the demand for these devices is rising.

North America is Expected to Dominate the Market Over the Forecast Period

The United States has been the most affected country across the world, as the non-emergent surgical procedures were put on hold, due to which the demand for these devices will decrease. However, the surgical procedures are resuming now with proper regulating guidelines, which will further increase the demand for these oxygenators, and the market growth will gradually rise.

North America is expected to dominate the overall oxygenators market throughout the forecast period. The major factors attributing to the growth are rise in the global prevalence of multiple cardiovascular indications like CAD, ischemic strokes, and atrial fibrillation, along with acute respiratory disorders such as acute respiratory distress syndrome (ARDS), due to a rise in chronic diseases, such as diabetes and obesity, necessitating the cardiopulmonary bypass procedures and thus, rise in demand for oxygenators. For instance, according to the American Heart Association Research Report 2018, heart disease accounts for one in seven deaths in the United States. Coronary heart disease is the leading cause (43.8%) of deaths attributable to cardiovascular disease in the United States, followed by stroke (16.8%), heart failure (9.0%), high blood pressure (9.4%), diseases of the arteries (3.1%), and other cardiovascular diseases (17.9%). This scenario is leading to a higher demand for better treatment with efficient medication, which is driving the market in the United States.

Furthermore, favorable reimbursement policies, approvals by the Food and Drug Administration (FDA), and availability of healthcare infrastructure in the region are expected to fuel the market during the forecast period.

Competitive Landscape

The oxygenators market is moderately competitive and consists of several major players. Few of the key players are launching new products with advanced technologies to compete with the existing products, while others are acquiring and partnering with other companies trending in the market. For instance, in January 2019, Terumo launched its smallest, lowest prime volume, adult oxygenator, the Capiox NX19 Oxygenator. The new oxygenator uses innovative UltraPrime technology that improves patient care during cardiopulmonary bypass procedures, which contributed to the company's growth in the cardiovascular surgery technologies market. Such product launches are expected to impel the oxygenator market's growth throughout the forecast period. Some of the companies currently dominating the market are Medtronic PLC, Terumo Medical Corporation, Getinge AB, EUROSETS SRL, and Livanova PLC.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Global Prevalence of Cardiopulmonary Disorders
    • 4.2.2 Increasing Geriatric Population, Rise in Global Healthcare Expenditure, and Growth in Disposable Income
    • 4.2.3 Availability of Technologically Advanced Products and Reimbursement Policies
  • 4.3 Market Restraints
    • 4.3.1 Adoption of Minimally Invasive Procedures and Risks Associated with Oxygenation Systems
    • 4.3.2 Stringent FDA Regulations
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size in Value)

  • 5.1 By Product Type
    • 5.1.1 Bubble Oxygenator
    • 5.1.2 Membrane Oxygenator
  • 5.2 By Application
    • 5.2.1 Respiratory
    • 5.2.2 Cardiac
    • 5.2.3 Extracorporeal Cardiopulmonary Resuscitation (ECPR)
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Chalice Medical Ltd
    • 6.1.2 EUROSETS SRL
    • 6.1.3 Getinge AB
    • 6.1.4 Livanova PLC
    • 6.1.5 Medtronic PLC
    • 6.1.6 Microport Scientific Corporation
    • 6.1.7 Nipro Medical Corporation
    • 6.1.8 Terumo Medical Corporation
    • 6.1.9 Braile Biomedica
    • 6.1.10 Xenios AG
    • 6.1.11 MC3 Cardiopulmonary
    • 6.1.12 Gen World Medical Devices
    • 6.1.13 Senko Medical Instrument Mfg Co. Ltd (MERA)
    • 6.1.14 Owgels Group

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q